세계의 더마 필러 시장(-2030년) : 브랜드(Juvederm, Sculptra, Radiesse), 제품(히알루론산, 콜라겐, PLLA), 시술(피부 회춘, 흉터 제거, 얼굴 및 바디 컨투어링), 최종사용자(피부과 클리닉, 미용센터, 메디컬 스파)

The derma fillers market is expected to experience significant growth, increasing from USD 4.1 billion in 2025 to USD 7.3 billion by 2030.

This growth is fueled by various factors, including demand for minimally invasive aesthetic procedures. Social media trends have normalized and mythologized the use of dermal fillers, particularly among Millennials and Generation Z. Plus, the prevalence of age-related skin issues, such as wrinkles and loss of volume, is stimulating the need for aesthetic treatments.

Fillers are being used for added indications (e.g., jawline, chin, hands) and the demand for customized treatments.

Continuous R&D and improved formulations (e.g., biodegradable and long-lasting injectables) and injection techniques have assured the long-term safety of fillers, making them even more appealing to practitioners and patients. These trends will continue to spur the growth of the global market.

"Natural dermal fillers dominated the market in 2024."

Natural dermal fillers, particularly those based on hyaluronic acid (HA), collagen, and other biodegradable, biocompatible materials, lead the market because they are highly biocompatible and have little risk of allergic reactions or side effects, all while being reversible as well. The worldwide trend toward less invasive aesthetic procedures for aesthetic improvements is a significant contributor to growth, whereby natural dermal fillers provide a non-surgical alternative for facial rejuvenation, wrinkle correction, and volume restoration. Natural dermal fillers are generation and consumer-driven, sourcing from consumer demand for safety, biocompatibility, and a natural-looking result, as well as consumer trends toward minimally invasive procedures, customizable treatments, and the popularity of social media and youth culture. Hyaluronic acid and other biodegradable fillers dominate natural dermal fillers and highlight consumer priorities, as natural fillers remain the preferred choice in the fast-growing derma fillers market.

"The dermatology clinics & hospitals segment held the largest share of the derma fillers market in 2024."

Dermatology clinics & hospitals are the primary end user in the derma fillers market, they are being fueled by increasing aesthetic demand with rising consumer interest in facial aesthetics and youthful appearance, product innovation, an expanding treatment indicator where clinics and hospitals are expanding their offerings to facial contouring, volume restoration, lip augmentation, or even hand rejuvenation, based on new product approvals and continuous patient needs. Other influences contributing to the performance, expertise, professional alliances and collaborations, and the socioeconomic environment have allowed procedures to be realized by patients and professionals alike. These drivers collectively provide domain and procedural growth and a lot of uptake in dermal filler procedures in both the clinics and hospital settings.

"The Asia Pacific region is expected to register the highest CAGR in the derma fillers market during the forecast period."

The Asia Pacific (APAC) region is one of the fastest emerging markets for dermal fillers, with growth driven by an unparalleled combination of demographic, economic, cultural, and technological factors. Demographic changes especially rising awareness and acceptance of aesthetic procedures (in particular among the younger and middle-aged consumer base), economic growth - resulting in a larger middle class with greater spending capacity, which makes non-invasive cosmetic skin treatment options accessible to a much wider audience, R&D and product releases of next-generation fillers which have significantly improved safety, efficacy and longevity, are all contributing factors leading to the growth of the APAC dermal fillers market. The exploding beauty consciousness, social media, continuous economic growth, aging populations, sustained innovation, medical tourism, supportive government policies, and developing healthcare infrastructures represent some of the major accelerators to the APAC dermal fillers market. The APAC derma fillers market is a large and very competitive market undergoing constant and rapid growth, driven by innovation.

A breakdown of the primary participants referred to for this report is provided below:

• By Company: Tier 1 (35%), Tier 2 (45%), and Tier 3 (20%)
• By Designation: C-level Executives (35%), Director-level Executives (25%), and Others (40%)
• By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%), and the Middle East & Africa (5%)

Prominent players in the derma fillers market include Allergan Aesthetics (US), Merz Pharma KGaA (Germany), Galderma (Switzerland), Sinclair Pharma (UK), Bioxis Pharmaceutical (France), Suneva Medical (US), Croma Pharma (Austria), Prollenium Medical Technologies (Canada), Dermax Med (China), Zimmer Aesthetics (Germany), Marllor Biomedical (Italy), MEDYTOX (South Korea), Revance Therapeutic (US), Dr. Korman Pharma (Israel), CGBio Co., Ltd. (South Korea), REGEN Biotech (UK), and BioScience GmbH (Germany), among others.

Research Coverage

• The report studies the derma fillers market based on brand, product, procedure, end user, and region.
• The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
• The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
• The report studies micro markets with respect to their growth trends, prospects, and contributions to the global derma fillers market.
• The report forecasts the revenue of market segments with respect to five major regions.

Key Benefits of Buying this Report

This report is valuable for both new and current players in the market, offering essential information to identify potential investment opportunities. It provides a comprehensive overview of both major and minor players, facilitating effective risk analysis and informed investment decisions. The report includes precise segmentation based on end users and geographical regions, offering detailed insights into niche market segments. Additionally, it highlights key trends, growth drivers, challenges, and opportunities, supporting strategic decision-making through a balanced analysis.

Through this report, readers get insightful views into the following parameters:

• Analysis of key drivers (Increasing demand for non-invasive aesthetic treatments, continued R&D has grown the sophistication of products, i.e., biodegradable longer-lasting fillers, improved injecting techniques), restraints (Cost barriers to treatment and the need for repeated treatments due to temporary nature of most derma fillers, concerns about adverse effects or complications can also impede market growth), opportunities (Exploration of biodegradable and bioresorbable fillers, potential for fillers to be used in conjunction with other aesthetic treatments, such as the use of botulinum toxin and laser therapy), challenges (the possibility of complications, such as vascular occlusion, granulomas or allergic reactions, can damage patient trust in procedures and also reputation and therefore negatively impact the market), relating to the growth of the derma fillers market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product & service launches in the derma fillers market.
• Market Development: Comprehensive information about lucrative markets - the report analyzes the derma fillers market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the derma fillers market
• Competitive Assessment: A comprehensive analysis of market share, product offerings, and leading strategies of major players, such as Allergan Aesthetics (US), Merz Pharma KGaA (Germany), Galderma (Switzerland), Croma Pharma (Austria), Sinclair Pharma (UK), Bioxis Pharmaceutical (France), Suneva Medical (US), Prollenium Medical Technologies (Canada), Dermax Med (China), Zimmer Aesthetics (Germany), Marllor Biomedical (Italy), MEDYTOX (South Korea), Revance Therapeutic (US), Dr. Korman Pharma (Israel), CGBio Co., Ltd. (South Korea), REGEN Biotech (UK), and BioScience GmbH (Germany).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY RESEARCH
    • 2.1.1.1 Key secondary sources
    • 2.1.1.2 Key data from secondary sources
    • 2.1.1.3 Objectives of secondary research
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Approach 1: Company revenue estimation
    • 2.2.1.2 Approach 2: Customer-based market estimation
    • 2.2.1.3 Approach 3: Primary interviews
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 GROWTH FORECAST
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 DERMA FILLERS MARKET OVERVIEW
• 4.2 NORTH AMERICA: DERMA FILLERS MARKET, BY PROCEDURE, 2025 VS. 2030 (USD MILLION)
• 4.3 EUROPE: DERMA FILLERS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
• 4.4 DERMA FILLERS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing adoption of minimally invasive and non-invasive aesthetic procedures
    • 5.2.1.2 Growing demand for aesthetic treatments among elderly and men
    • 5.2.1.3 Rising acceptance and normalization of fillers among millennials and Gen Z fueled by social media
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Risk of infection and safety concerns
    • 5.2.2.2 Complex regulatory framework and compliance standards
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growth opportunities in emerging markets
    • 5.2.3.2 Launch of new technologies and products
  • 5.2.4 CHALLENGES
    • 5.2.4.1 High cost of treatments and devices
    • 5.2.4.2 Social and cultural barriers
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND, BY PRODUCT
  • 5.4.2 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
  • 5.4.3 AVERAGE SELLING PRICE TREND, BY REGION
• 5.5 VALUE CHAIN ANALYSIS
  • 5.5.1 RESEARCH & DEVELOPMENT
  • 5.5.2 RAW MATERIAL PROCUREMENT AND PRODUCT MANUFACTURING
  • 5.5.3 DISTRIBUTION, MARKETING & SALES, AND AFTER-SALES SERVICES
• 5.6 SUPPLY CHAIN ANALYSIS
  • 5.6.1 PROMINENT COMPANIES
  • 5.6.2 SMALL AND MEDIUM-SIZED ENTERPRISES
  • 5.6.3 END USERS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Advanced Hyaluronic Acid (HA) cross-linking
    • 5.9.1.2 Polymethylmethacrylate (PMMA) fillers
    • 5.9.1.3 Bio-stimulatory fillers
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Laser resurfacing
    • 5.9.2.2 Microneedling
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 3D imaging and AI-based facial mapping
• 5.10 PATENT ANALYSIS
• 5.11 TRADE ANALYSIS
  • 5.11.1 IMPORT SCENARIO (HS CODE 330499)
  • 5.11.2 EXPORT SCENARIO (HS CODE 330499)
• 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.13 CASE STUDY ANALYSIS
  • 5.13.1 COMMERCIAL PARTNERSHIPS FOR AESTHETIC PRODUCT SALES
  • 5.13.2 DIVERSIFICATION OF BUSINESS TO MEET CUSTOMER DEMANDS
  • 5.13.3 COLLABORATIONS WITH SMES FOR STREAMLINING LASER-BASED DEVICES
• 5.14 REGULATORY LANDSCAPE
  • 5.14.1 REGULATORY ANALYSIS
    • 5.14.1.1 North America
      • 5.14.1.1.1 US
      • 5.14.1.1.2 Canada
    • 5.14.1.2 Europe
      • 5.14.1.2.1 UK
      • 5.14.1.2.2 France
      • 5.14.1.2.3 Germany
    • 5.14.1.3 Asia Pacific
      • 5.14.1.3.1 Japan
      • 5.14.1.3.2 India
    • 5.14.1.4 Rest of the World
      • 5.14.1.4.1 Brazil
      • 5.14.1.4.2 UAE
  • 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.15 PORTER'S FIVE FORCES ANALYSIS
  • 5.15.1 BARGAINING POWER OF SUPPLIERS
  • 5.15.2 BARGAINING POWER OF BUYERS
  • 5.15.3 THREAT OF NEW ENTRANTS
  • 5.15.4 THREAT OF SUBSTITUTES
  • 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.16.2 BUYING CRITERIA
• 5.17 REIMBURSEMENT SCENARIO
• 5.18 UNMET NEEDS AND KEY PAIN POINTS
• 5.19 IMPACT OF AI ON DERMA FILLERS MARKET
  • 5.19.1 INTRODUCTION
  • 5.19.2 MARKET POTENTIAL OF AI ON DERMA FILLERS ECOSYSTEM
  • 5.19.3 AI USE CASES
  • 5.19.4 KEY COMPANIES IMPLEMENTING AI
  • 5.19.5 FUTURE OF GENERATIVE AI IN DERMA FILLERS MARKET
• 5.20 US TARIFF 2025
  • 5.20.1 INTRODUCTION
  • 5.20.2 KEY TARIFF RATES
  • 5.20.3 PRICE IMPACT ANALYSIS
  • 5.20.4 IMPACT ON COUNTRY/REGION
    • 5.20.4.1 US
    • 5.20.4.2 Europe
    • 5.20.4.3 Asia Pacific
  • 5.20.5 IMPACT ON END-USE INDUSTRIES

6 DERMA FILLERS MARKET, BY BRAND

• 6.1 INTRODUCTION
• 6.2 JUVEDERM
  • 6.2.1 WIDE INDICATION COVERAGE AND GLOBAL REACH TO CONTRIBUTE TO GROWTH
• 6.3 RESTYLANE
  • 6.3.1 FASTER ONSET DURATION AND LONG-LASTING EFFECT TO ENCOURAGE GROWTH
• 6.4 RHA COLLECTION
  • 6.4.1 GROWING DESIRE FOR NATURAL EXPRESSIONS TO BOOST MARKET
• 6.5 SCULPTRA
  • 6.5.1 INCREASED ADOPTION OF SCULPTRA AMONG ADVANCED INJECTORS TO BOLSTER GROWTH
• 6.6 RADIESSE
  • 6.6.1 STABLE SUCCESS RATES AND DESIRED RESULTS TO SPUR GROWTH
• 6.7 LANLUMA
  • 6.7.1 EXPANDED USE CASES IN BODY CONTOURING APPLICATIONS TO INTENSIFY GROWTH
• 6.8 BELLAFILL
  • 6.8.1 USE OF BELLAFILL FOR TREATING DEEP ACNE SCARS AND NASOLABIAL FOLDS TO FOSTER GROWTH
• 6.9 OTHER BRANDS

7 DERMA FILLERS MARKET, BY PRODUCT TYPE

• 7.1 INTRODUCTION
• 7.2 NATURAL DERMAL FILLERS
  • 7.2.1 HYALURONIC ACID FILLERS
    • 7.2.1.1 Wide clinical acceptance and safety profile to aid growth
  • 7.2.2 COLLAGEN FILLERS
    • 7.2.2.1 Ability to provide structural support and improved skin texture to boost market
• 7.3 SYNTHETIC DERMAL FILLERS
  • 7.3.1 CALCIUM HYDROXYLAPATITE (CAHA) FILLERS
    • 7.3.1.1 Long-term collagen stimulation property to augment growth
  • 7.3.2 POLY-L-LACTIC ACID (PLLA) FILLERS
    • 7.3.2.1 Increasing desire for natural, progressive rejuvenation to stimulate growth
  • 7.3.3 POLYMETHYL METHACRYLATE (PMMA) FILLERS
    • 7.3.3.1 Long-lasting structural correction ability to favor growth
  • 7.3.4 POLYNUCLEOTIDE FILLERS
    • 7.3.4.1 Rising preference for skin revitalization procedures to fuel market
  • 7.3.5 OTHER SYNTHETIC FILLERS

8 DERMA FILLERS MARKET, BY PROCEDURE

• 8.1 INTRODUCTION
• 8.2 SKIN REJUVENATION
  • 8.2.1 INCREASING ACCEPTANCE AND REPEATABILITY OF SKIN PROCEDURES TO FACILITATE GROWTH
• 8.3 FACE & BODY CONTOURING
  • 8.3.1 RISING NUMBER OF FACIAL AND BODY CONTOURING-RELATED PROCEDURES TO PROMOTE GROWTH
• 8.4 LIP AUGMENTATION
  • 8.4.1 NEED FOR REPETITIVE CYCLES TO MAINTAIN DESIRED LOOK TO PROPEL MARKET
• 8.5 OTHER PROCEDURES

9 DERMA FILLERS MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 DERMATOLOGY CLINICS & HOSPITALS
  • 9.2.1 RISING TREND OF MEDICAL TOURISM AND PLASTIC SURGERY TO SUPPORT GROWTH
• 9.3 BEAUTY CENTERS
  • 9.3.1 GROWING INCLINATION TOWARD CUSTOMIZED TREATMENT TO DRIVE MARKET
• 9.4 MEDICAL SPAS
  • 9.4.1 INCREASING FOCUS ON CONVENIENCE, TREATMENT FLEXIBILITY, AND COST SAVING TO SPUR GROWTH
• 9.5 OTHER END USERS

10 DERMA FILLERS MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Rising geriatric population to spur growth
  • 10.2.3 CANADA
    • 10.2.3.1 Preference of aging individuals to reduce aging signs to promote growth
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Large consumer base to expedite growth
  • 10.3.3 UK
    • 10.3.3.1 Increasing volume-enhancement treatments to support growth
  • 10.3.4 FRANCE
    • 10.3.4.1 Favorable demographics and increased acceptance of non-surgical procedures to aid growth
  • 10.3.5 ITALY
    • 10.3.5.1 Growing acceptance of minimally invasive procedures to fuel market
  • 10.3.6 SPAIN
    • 10.3.6.1 Increasing availability of safe and minimally invasive treatments to augment growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 JAPAN
    • 10.4.2.1 Growing trend of volume restoration and wrinkle correction to boost market
  • 10.4.3 CHINA
    • 10.4.3.1 Surging demand for aesthetic procedures to accelerate growth
  • 10.4.4 INDIA
    • 10.4.4.1 Rapid urbanization and proliferation of clinics to stimulate growth
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Rising safety standards for non-surgical cosmetic procedures to encourage growth
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Robust medical infrastructure to speed up growth
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Cultural normalization of aesthetic treatments to contribute to growth
  • 10.5.3 MEXICO
    • 10.5.3.1 Increasing inflow of medical tourists to sustain growth
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.6.2 GCC COUNTRIES
    • 10.6.2.1 Booming aesthetic tourism sector to facilitate growth
  • 10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 11.3 REVENUE ANALYSIS, 2020-2024
• 11.4 MARKET SHARE ANALYSIS, 2024
  • 11.4.1 NATURAL DERMA FILLERS MARKET SHARE
  • 11.4.2 SYNTHETIC DERMAL FILLERS MARKET SHARE
• 11.5 COMPANY VALUATION AND FINANCIAL METRICS
• 11.6 BRAND/PRODUCT COMPARISON
• 11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 11.7.1 STARS
  • 11.7.2 EMERGING LEADERS
  • 11.7.3 PERVASIVE PLAYERS
  • 11.7.4 PARTICIPANTS
  • 11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 11.7.5.1 Company footprint
    • 11.7.5.2 Region footprint
    • 11.7.5.3 Product type footprint
    • 11.7.5.4 Procedure footprint
    • 11.7.5.5 End-user footprint
• 11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 11.8.1 PROGRESSIVE COMPANIES
  • 11.8.2 RESPONSIVE COMPANIES
  • 11.8.3 DYNAMIC COMPANIES
  • 11.8.4 STARTING BLOCKS
  • 11.8.5 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
    • 11.8.5.1 Detailed list of key startups/SMEs
    • 11.8.5.2 Competitive benchmarking of key startups/SMEs
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 11.9.2 DEALS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 ABBVIE INC.
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product launches and approvals
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 GALDERMA
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product launches and approvals
      • 12.1.2.3.2 Deals
      • 12.1.2.3.3 Expansions
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses and competitive threats
  • 12.1.3 MERZ PHARMA
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Expansions
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 SILCLAIR PHARMA
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 MnM view
      • 12.1.4.3.1 Key strengths
      • 12.1.4.3.2 Strategic choices
      • 12.1.4.3.3 Weaknesses and competitive threats
  • 12.1.5 REVANCE
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product launches and approvals
      • 12.1.5.3.2 Deals
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses and competitive threats
  • 12.1.6 CROMA PHARMA
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
  • 12.1.7 EVOLUS, INC.
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Product launches and approvals
  • 12.1.8 HUGEL, INC.
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
  • 12.1.9 MEDYTOX
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
  • 12.1.10 BIOXIS PHARMACEUTICAL
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
  • 12.1.11 ZIMMER MEDIZINSYSTEME GMBH
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
  • 12.1.12 CUTERA, INC.
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
    • 12.1.12.3 Recent developments
      • 12.1.12.3.1 Product launches and approvals
      • 12.1.12.3.2 Deals
  • 12.1.13 SCIVISION BIOTECH INC.
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
  • 12.1.14 BRIDGEPOINT GROUP PLC
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
  • 12.1.15 ANIKA THERAPEUTICS, INC.
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
• 12.2 OTHER PLAYERS
  • 12.2.1 TIGER AESTHETICS MEDICAL
  • 12.2.2 PROLLENIUM MEDICAL TECHNOLOGIES
  • 12.2.3 BIOSCIENCE GMBH
  • 12.2.4 DERMAX
  • 12.2.5 TEOXANE
  • 12.2.6 DR. KORMAN LABORATORIES LTD.
  • 12.2.7 CYTOPHIL, INC.
  • 12.2.8 TELETA PHARMA
  • 12.2.9 IBSA DERMA
  • 12.2.10 NEOGENESIS
  • 12.2.11 CGBIO, CO., LTD.

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS